Toggle light / dark theme

Dopamine ‘gas pedal’ and serotonin ‘brake’ team up to accelerate learning

Mice learn best when the opponent opposing forces of dopamine and serotonin work together, a new study shows, helping to resolve long-standing questions about the neuromodulators’ relationship.

In the intricate dance of learning and motivation, two key brain chemicals—dopamine (DA) and serotonin (5HT)—play opposing yet deeply interconnected roles. Scientists have long speculated how these neuromodulators work together to shape our ability to form new associations, but testing these theories directly has been a challenge.

Now, researchers have developed a new mouse model that allows them to simultaneously study both dopamine and serotonin neurons in the brain. Their experiments focused on the nucleus accumbens (NAc), a region known for processing rewards. By monitoring neural activity, they found that receiving a reward boosts dopamine signals while simultaneously suppressing serotonin signals.

To understand how this dynamic affects learning, the team used optogenetics—a technique that uses light to control brain activity. They found that disrupting dopamine or serotonin alone caused only mild learning impairments. However, when both signals were suppressed together, the mice struggled significantly to learn from rewards. On the flip side, artificially recreating both dopamine and serotonin responses helped the mice learn more effectively than manipulating either signal alone.

These findings reveal that dopamine and serotonin work in opposition to control reinforcement and learning. Instead of acting in isolation, they create a delicate balance that shapes how we associate actions with rewards—providing new insights into how the brain learns and adapts.


Mice learn fastest and most reliably when they experience an increase in dopamine paired with an inhibition of serotonin, a new study shows.

Sex as a formality: Study shows male stick insects have lost their reproductive function

While most animals reproduce sexually, some species rely solely on females for parthenogenetic reproduction. Even in these species, rare males occasionally appear. Whether these males retain reproductive functions is a key question in understanding the evolution of reproductive strategies.

A new study published in Ecology by a research team led by Assistant Professor Tomonari Nozaki from the National Institute for Basic Biology, Professor Kenji Suetsugu from Kobe University, and Associate Professor Shingo Kaneko from Fukushima University provides insight into this question. The researchers focused on the rare males of Ramulus mikado, a stick insect species in Japan, where parthenogenesis is predominant. Their analysis of male reproductive behavior reveals new findings.

New “Humanized” Mice Brings Scientists Closer to Reversing Aging

Washington State University scientists have developed genetically engineered mice that could help accelerate anti-aging research.

Globally, researchers are striving to unlock the secrets of extending human lifespan at the cellular level, where aging occurs gradually due to the shortening of telomeres—the protective caps at the ends of chromosomes that function like shoelace tips, preventing unraveling. As telomeres shorten over time, cells lose their ability to divide for healthy growth, and some eventually begin to die.

However, studying telomeres at the cellular level has been challenging in humans.

Yellowstone’s Super-Hot Water May Hold The Secrets of Earth’s First Breath

Microbial life in Yellowstone’s Lower Geyser Basin may hold clues to the evolution of life’s exploitation of oxygen, according to a recent analysis by researchers from Montana State University.

T he inhabitants of the basin’s Octopus and Conch Springs live in kelp-like, gelatinous ‘streamer’ structures that wiggle furiously in superheated currents, which hover around 88 degrees Celsius (190 degrees Farenheit). Genetically similar to ancient bacteria and archaea, t heir existence is a window into the primordial soup from which life emerged.

While these microbial communities share many traits, the springs’ environments are different in a few fundamental ways.

How a former navy mechanic defied the genetic odds of inherited Alzheimer’s disease

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual carrying the presenilin 2 (PSEN2) p. Asn141Ile mutation, a genetic variant known to cause dominantly inherited Alzheimer’s disease (DIAD). The high risk individual, despite being 18 years past the expected age of clinical onset, has remained cognitively intact. Researchers investigated genetic, neuroimaging, and biomarker data to understand potential protective mechanisms.

Unlike typical DIAD progression, in this case was confined to the occipital lobe without spreading, suggesting a possible explanation for the lack of cognitive decline.

DIAD results from highly penetrant mutations in (APP), presenilin 1 (PSEN1), or PSEN2, which lead to abnormal amyloid-β processing and early-onset Alzheimer’s disease. The Dominantly Inherited Alzheimer Network (DIAN) was established to track DIAD mutation carriers and assess clinical, cognitive, and biomarker changes over time.

Some viruses ‘freeze’ their RNA to replicate, study finds

They say that change takes time. Well, that’s not the case for RNA. The small biological molecule acts like a switchboard operator, capable of changing its shape every few milliseconds so it can manipulate biological functions in the body. It has big jobs to carry out, after all, like copying genetic information into every living cell and activating the immune response.

A new multidisciplinary study from biophysicists and virologists at the UNC School of Medicine challenges this idea of shape-shifting RNA. Helen Lazear, Ph.D., associate professor of microbiology and immunology, and Qi Zhang, Ph.D., professor of biochemistry and biophysics, have discovered that a type of RNA in Zika virus, a mosquito-borne virus, can essentially freeze itself in time in an effort to make more copies of itself and further its spread in the body.

Their findings have not only sent ripples through the field of virology, but it has also given researchers new ammunition in the fight against RNA viruses. Their study, which was published in Nature Chemical Biology, paves the way for new therapies that can “unfreeze” these RNA structures to combat other mosquito-borne RNA viruses.

New Research Shatters the Perfect Pitch Myth

For decades, people believed absolute pitch was an exclusive ability granted only to those with the right genetics or early music training. But new research from the University of Surrey proves otherwise. It’s been a long-held belief that absolute pitch — the ability to identify musical notes without a reference — is a rare talent limited to those with specific genetic traits or early musical training. However, new research from the University of Surrey challenges this idea, showing that adults can develop absolute pitch through dedicated training.

Visceral Fat Removal Extends Lifespan: Which Factors May Reduce Visceral Fat?

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

Primary Prevention Trial

While the trial is limited to members of families with genetic mutations that all but guarantee they will develop Alzheimer’s at a young age, typically in their 30s, 40s or 50s, the researchers expect that the study’s results will inform prevention and treatment efforts for all forms of Alzheimer’s disease.

Called the Primary Prevention Trial, the new study investigates whether remternetug — an investigational antibody being developed by Eli Lilly and Company — can remove plaques of a key Alzheimer’s protein called amyloid beta from the brain or block them from accumulating in the first place. Both genetic and nongenetic forms of Alzheimer’s disease start with amyloid slowly collecting in the brain two decades before memory and thinking problems arise. By clearing out low levels of amyloid beta plaques or preventing them from accumulating during the early, asymptomatic phase of the disease, or both, the researchers hope to interrupt the disease process at the earliest stage and spare people from ever developing symptoms.

“We have seen tremendous progress in the treatment of Alzheimer disease in the past few years,” said Eric McDade, DO, a professor of neurology and the trial’s principal investigator. “Two amyloid-targeting drugs were shown to slow symptoms of the disease and have now been approved by the Food and Drug Administration (FDA) as treatments for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. This provides strong support for our hypothesis that intervening when amyloid beta plaques are at the very earliest stage, long before symptoms arise, could prevent symptoms from emerging in the first place.”

The trial is part of the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (Knight Family DIAN-TU), a clinical trials platform designed to find medicines to prevent or treat Alzheimer’s disease. It is closely associated with DIAN, a National Institutes of Health (NIH)-funded international research network led by WashU Medicine that involves research institutes in North America, Australia, Europe, Asia and South America. DIAN follows families with mutations in any of three genes that cause Alzheimer’s at a young age. A child born into such a family has a 50% chance of inheriting such a mutation, and those who do so typically develop signs of dementia near the same age his or her parent did. All the participants in the Primary Prevention Trial come from such families.

“My grandfather passed away from Alzheimer’s, and so did his mother and all but one of his brothers,” said Hannah Richardson, 24, a participant in the Primary Prevention Trial. “My mom and my uncle have been participating in DIAN trials since I was about 10 years old. My mom was always very open about her diagnosis and how it spurred her advocacy for Alzheimer’s research, and I’ve always known I wanted to follow in her footsteps. I am happy to be involved in the Primary Prevention Trial and be involved in research because I know how important it is.”